CMT Post-Procedure Cream™- the first neurocosmetic post-procedure cream proven to decrease pain perception and reduce downtime following chemical peels, microneedling and laser treatments.† CMT Post-Procedure Cream™ features patent-pending neurocosmetic technology that helps skin recover better faster, improving the patient experience and increasing the likelihood that the recommended number of treatments will be completed.
This breakthrough formula targets the pathways that trigger communication between the skin and the brain, interrupting the skin’s pain cycle by increasing beta-endorphins and suppressing the transient receptor potential vanilloid 1 (TRPV1) to reduce pain perception and discomfort while regenerating the epidermal barrier so compromised skin can recover faster.
- Patent-pending neurocosmetic technology decreases pain perception post-treatment by interrupting the skin’s pain cycle
- Helps compromised skin recover faster by regenerating the epidermal barrier for faster recovery
- Reduces downtime and improves the patient experience after the following CMT professional procedures†: Chemical (Peels), Mechanical (Microneedling, Microdermabrasion), and Thermal Energy (Fractionated CO2, Erbium, RF, IPL)
- Helps replenish and reset the skin’s native microbiome, promoting longterm skin health
- 0.5 OZ | 14 g
Who benefits? Anyone who is considering an in-office procedure but may be concerned about the length of recovery or post-treatment discomfort.
Skin Benefits
RELIEF: Decreases pain perception by interrupting the pain cycle
- Counteracts the effects of skin stress and stimulates the expression and release of beta-endorphins while suppressing transient receptor potential vanilloid 1 (TRPV1) which can decrease pain perception
- Improves patient discomfort associated with itching, stinging, burning
- Supports the recovery process by actively relaxing and calming skin and providing a feeling of comfort
- Reduces thermal sensitivity and perception of heat
RECOVERY: Reduces downtime by helping compromised skin recover better, faster
- Regenerates the epidermal barrier and helps replenish the native microbiome for faster recovery
- Downregulates Matrix Metalloproteinase 1 (MMP1) for optimal re-epithelization and protects dermal proteins like collagen
- Increases the production of adhesion proteins which promote cell binding and skin renewal to support barrier repair
- Improves skin moisturization to assist with re-epithelization
CLINICAL STUDIES & SUPPORTING DATA
SUPERFICIAL & MEDIUM-DEPTH CHEMICAL PEEL TREATMENTS (CHEMICAL)
Superficial Peel
IMMEDIATELY1 (post-procedure)
88% of subjects favorably agreed that the product1 :
- Provided immediate relief from dryness
- Reduced irritation on my skin
Medium-Depth Peel
IMMEDIATELY1 (post-procedure)
96% of subjects favorably agreed that the product1 :
- Provided immediate relief from dryness
- Reduced irritation on my skin
*NOTE: We do not currently have any before and after photos for the chemical peel treatments.
RADIOFREQUENCY MICRONEEDLING TREATMENT (MECHANICAL)
OVERALL: (after 7 days of use twice daily on face and neck)
100% of subjects favorably agreed “the experience with product and procedure was positive and I would be interested in returning for a second treatment”
IMMEDIATELY1 (post-procedure)
83% of subjects favorably agreed that the product1 :
- Was gentle on my skin
- Comforted my skin post-procedure
- Reduced irritation on the skin post-procedure
- Moisturized my skin immediately
AFTER 24 HOURS1 (post-procedure)
100% of subjects favorably agreed that the product1 :
- Relieved discomfort on my skin
- Calmed my skin
- Provided nourishing hydration to my skin
AFTER 24 HOURS1 (post-procedure)
83% of subjects favorably agreed that the product1 :
- Soothed my skin from burning sensation
- Reduced irritation
- Provided relief to dry, damaged skin
- Eased my recovery time post-procedure
- Improved the appearance of my skin
Footnote: Clinical study procedure pairing with Morpheus8® by InMode. Revision Skincare® does not manufacture Morpheus8®. The use of the product or company name does not imply any affiliation with or endorsement by them. 14-day randomized, single - center, double -blind, controlled clinical case study with 11 female subjects 35 -63 years old, Fitzpatrick skintypes II-IV, and moderate global facial photo damage ( Grade II or III Gloagau Scale) [ completed clinical case study]
1Data on file. Results may vary.